SCHEDULE: State Street Discloses 5.3% Stake in Agios Pharma

State Street Corporation has reported a 5.3% beneficial ownership stake in Agios Pharmaceuticals Inc., holding 3,108,145 common shares as of December 31, 2025.

Summary

• State Street Corporation, a Massachusetts-based entity, reported beneficial ownership of 3,108,145 shares of common stock in Agios Pharmaceuticals Inc.
• This represents 5.3% of the class of securities.
• The filing indicates shared voting power over 2,926,200 shares and shared dispositive power over 3,108,145 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, factual disclosure of an institutional ownership stake. It provides no direct positive or negative operational or financial news for Agios Pharmaceuticals.

Positives

• Disclosure of a significant institutional ownership stake (5.3%) by State Street Corporation, a major financial institution, may signal confidence in Agios Pharmaceuticals.
• The filing confirms that the shares are held in the ordinary course of business, not for activist purposes.

Negatives

• No specific negative information regarding Agios Pharmaceuticals is contained within this beneficial ownership report.

Risks

• No specific risks related to Agios Pharmaceuticals are detailed in this beneficial ownership filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Agios Pharmaceuticals' future performance or operations.

Management Comments

• "I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

StockSavvy.ai notes that State Street Corporation is one of the world's largest institutional asset managers, often holding significant passive stakes in publicly traded companies through its various investment advisory subsidiaries. This filing reflects a standard disclosure of a substantial passive investment in Agios Pharmaceuticals, a biotechnology company focused on developing medicines for rare diseases. Such disclosures are common for large index funds or actively managed funds that cross the 5% ownership threshold.

Comparison to Industry Standards

• This Schedule 13G filing is a disclosure of beneficial ownership and does not provide performance metrics for Agios Pharmaceuticals that would allow for a direct comparison to industry standards or specific comparable companies/projects. The filing itself adheres to SEC reporting standards for institutional investors.

Stakeholder Impact

• Shareholders of Agios Pharmaceuticals may view State Street's significant stake as a sign of institutional confidence, potentially contributing to market stability.
• Employees, customers, suppliers, and creditors are unlikely to be directly impacted by this beneficial ownership disclosure.

Next Steps

• No specific future actions or milestones for Agios Pharmaceuticals are mentioned in this filing.

Key Dates

Keywords

Agios Pharmaceuticals, State Street Corporation, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Pharmaceuticals, Biotechnology